Respicardia

OverviewSuggest Edit

Respicardia is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time.
TypePrivate
Founded2006
HQHopkins, MN, US
Websiterespicardia.com

Latest Updates

Employees (est.) (Jul 2021)78(-2%)
Cybersecurity ratingCMore

Key People/Management at Respicardia

B. Kristine Johnson

B. Kristine Johnson

Director
Peter Sommerness

Peter Sommerness

President and CEO, Director
Tim Hauch

Tim Hauch

Chief Financial Officer
Kirk Nielsen

Kirk Nielsen

Director
Robin Germany

Robin Germany

Chief Medical Officer
Jonathan A. Rennert

Jonathan A. Rennert

Director
Show more

Respicardia Office Locations

Respicardia has an office in Hopkins
Hopkins, MN, US (HQ)
12400 Whitewater Dr #150
Show all (1)

Respicardia Financials and Metrics

Summary Metrics

Founding Date

2006

Respicardia total Funding

$149.1 m

Respicardia latest funding size

$58.5 m

Time since last funding

4 years ago

Respicardia investors

Respicardia's latest funding round in December 2017 was reported to be $58.5 m. In total, Respicardia has raised $149.1 m
Show all financial metrics

Respicardia Cybersecurity Score

Cybersecurity ratingPremium dataset

C

70/100

SecurityScorecard logo

Respicardia Online and Social Media Presence

Embed Graph

Respicardia News and Updates

Respicardia Announces Highmark Coverage for the remedē® System in Patients with Central Sleep Apnea

MINNETONKA, Minn., Jan. 7, 2021 /PRNewswire/ -- Respicardia, Inc., the manufacturer of the only FDA-approved active implantable system for the treatment of central sleep apnea (CSA), announced today that Highmark Blue Cross Blue Shield and its affiliates will provide coverage for the...

CMS Grants New Technology Add-on Payment to the remedē® System for the Treatment of Central Sleep Apnea

MINNETONKA, Minn., Aug. 6, 2018 /PRNewswire/ -- Respicardia, Inc., a medical technology company developing innovative therapies that improve cardiovascular health, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved a New Technology Add-On Payment (NTAP) ...

Respicardia Blogs

MIKE’S SLEEP APNEA DISRUPTED HIS SLEEP AND LIFESTYLE UNTIL HE FOUND A THERAPY OFFERED AT HIS LOCAL VA HOSPITAL

Mike shares how the daily disruptions caused by his undiagnosed CSA led him to a sleep study and an eventual treatment. The post MIKE’S SLEEP APNEA DISRUPTED HIS SLEEP AND LIFESTYLE UNTIL HE FOUND A THERAPY OFFERED AT HIS LOCAL VA HOSPITAL appeared first on Respicardia.

THE PREVALENCE OF CENTRAL SLEEP APNEA IN A COMMUNITY BASED STUDY

A large community-based study was conducted to test the prevalence of a particular form of central sleep apnea (CSA): CSA and cheyne-stokes respiration (CSR) using current clinical definitions. The study was unique in that it was conducted in a community setting instead of a controlled clinical envi…

ZOLL Announces Five-Year Study Confirming Safety, Efficacy and Beneficial Effects of Long-Term Transvenous Phrenic Nerve Stimulation (the remedē System)

ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the peer-reviewed journal Nature and Science of Sleep has published five-year results from the remedē System Post Approval Study. The post <a href="https://www.zoll.com/news-releases/2021/05/17/zoll-announces-five-year-study-confirming-safety-efficacy-beneficial-effects-long-term-transvenous…

UNDERSTANDING COMMERCIAL AND MEDICARE ADVANTAGE INSURANCE COVERAGE FOR THE remedē® SYSTEM

For people with central sleep apnea, understanding exactly which treatment options are covered under your insurance policy can be time- consuming. Every insurance plan is different, but this blog is designed to help those of you with Medicare Advantage or Commercial insurance understand the prior au…

ZOLL Medical Corporation acquires Respicardia, Inc.

ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has acquired Respicardia, Inc., a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea (CSA). The post ZOL…

CENTRAL SLEEP APNEA (CSA) AND EXCESSIVE DAYTIME SLEEPINESS

Excessive daytime sleepiness (EDS) is a potential symptom of sleep apnea. This blog will focus specifically on how daytime sleepiness impacts people with central sleep apnea (CSA). The post CENTRAL SLEEP APNEA (CSA) AND EXCESSIVE DAYTIME SLEEPINESS appeared first on Respicardia.
Show more

Respicardia Frequently Asked Questions

  • When was Respicardia founded?

    Respicardia was founded in 2006.

  • Who are Respicardia key executives?

    Respicardia's key executives are B. Kristine Johnson, Peter Sommerness and Tim Hauch.

  • How many employees does Respicardia have?

    Respicardia has 78 employees.

  • Who are Respicardia competitors?

    Competitors of Respicardia include Tao Technologies, SinuSys and AdaptHealth.

  • Where is Respicardia headquarters?

    Respicardia headquarters is located at 12400 Whitewater Dr #150, Hopkins.

  • Where are Respicardia offices?

    Respicardia has an office in Hopkins.

  • How many offices does Respicardia have?

    Respicardia has 1 office.